12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study
Transplant International · 2025
DOI: 10.3389/ti.2025.14312 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Transplant International, 2025. Verfasst von Ondrej Viklicky und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Desensitization, Immunologic, Graft Rejection, Immunoglobulins, Intravenous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Intravenous immunoglobulins (IVIG) are commonly used in peri-transplant desensitization, but evidence supporting their efficacy is limited. We conducted a prospective, randomized single-center, open-label, Phase IIIb non-inferiority clinical pilot trial to compare the efficacy of IVIG (administered at a dose of 3 × 0.5 g/kg) versus no IVIG, in conjunction with rabbit anti-thymocyte globulin (5–7 mg/kg) induction, in pre-sensitized patients with donor-specific antibodies who had negative pre-transplantation Flow- and CDC-crossmatches, between July 2020 and November 2022. The primary endpoint was the rate of efficacy failure, defined as biopsy-proven rejection within 12-month post-transplant. Secondary endpoints included the incidence of rejection at protocol biopsies, evaluated by histology and biopsy-based transcripts diagnostics. Of the screened patients, 53 (72.6%) were excluded due to crossmatch positivity. Ten patients were randomized to the IVIG+, and 7 to the IVIG-arm. The trial was prematurely terminated due to futility at interim analysis. In the IVIG-arm, 3 patients (43%) experienced the primary endpoint compared to none in the IVIG+ arm (p = 0.026). MMDx identified one molecular ABMR in the IVIG+ and 2 in the IVIG-arm in 12-month protocol biopsies. There was one graft loss in the IVIG-arm. The results of this pilot study, although not definitive, do not support the use of IVIG-sparing regimens in HLA-incompatible kidney transplantation (NCT04302805). This study is registered on ClinicalTrials.gov under the identifier NCT04302805.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia.
- Transplantation Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czechia.
- Department of Data Science, Institute for Clinical and Experimental Medicine, Prague, Czechia.
- Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia.
- Department of Transplantation Surgery, Institute for Clinical and Experimental Medicine, Prague, Czechia.
Zitieren
APA
Viklicky, O., Zahradka, I., Mares, J., Slatinska, J., Parikova, A., Petr, V., Roder, M., Jaklova, K., Osickova, K., Janousek, L., & Hruba, P. (2025). 12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study. Transplant International. https://doi.org/10.3389/ti.2025.14312
Vancouver
Viklicky O, Zahradka I, Mares J, Slatinska J, Parikova A, Petr V, et al. 12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study. Transplant International. 2025. doi:10.3389/ti.2025.14312
BibTeX
@article{Viklicky2025,
author = {Viklicky, Ondrej and Zahradka, Ivan and Mares, Jan and Slatinska, Janka and Parikova, Alena and Petr, Vojtech and Roder, Matej and Jaklova, Katerina and Osickova, Klara and Janousek, Libor and Hruba, Petra},
title = {12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study},
journal = {Transplant International},
year = {2025},
doi = {10.3389/ti.2025.14312}
}
EUVIMED